Shifting focus from ideality to reality: a qualitative study on how quality of life is defined by premanifest and manifest Huntington's disease gene expansion carriers
Pearl J. C. van Lonkhuizen,Anne-Wil Heemskerk,Leanne Slutter,Erik van Duijn,Susanne T. de Bot,Niels H. Chavannes,Eline Meijer,on behalf of the HEALTHE-RND consortium,Niko Vegt,Niels Chavannes,Anne- Wil Heemskerk,Susanne T. de Bot,Pearl J. C. van Lonkhuizen,Niko Vegt,Stephanie Feleus,Esther C Arendts,Amy Putman,G. Bernhard Landwehrmeyer,Alzbeta Mühlbäck,Wiebke Frank,Franziska Steck,Jiří Klempíř,Romama Konvalinková,Eva Bezuchová,Kristýna Dolečková,Olga Klempířová,Jan Roth,Olga Ulmanová,Ferdinando Squitieri,Sabrina Maffi,Eugenia Scaricamazza,Simone Migliore,Chiara Giorgio,Barbara D’Alessio,Melissa Casella,Jennifer Hoblyn,Muthukumaran Thangaramanujam,Tom Burke,Emer O’Malley,Stephen McKenna,Ian McKenna,Jeanette Thorpe,Anna Coffey,Ramona Moldovan,Peter Foley,Jacqueline Kerr
DOI: https://doi.org/10.1186/s13023-024-03461-x
2024-12-01
Orphanet Journal of Rare Diseases
Abstract:Understanding quality of life (QoL) is important in diseases for which there is no cure to date, such as Huntington's disease (HD). A deeper level of understanding is, however, compromised by the lack of studies examining QoL from the perspectives of HD gene expansion carriers (HDGECs). Only a few qualitative studies on QoL in HD have been performed, yet none investigated how QoL is defined by HDGECs themselves.
genetics & heredity,medicine, research & experimental